Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03093922 · ClinicalTrials.gov registry record · Phase 2
A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer
A Phase 2 study of Urothelial Carcinoma and Locally Advanced, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 9
- Study locations
NCT03093922: Active Phase 2 study of Urothelial Carcinoma and Locally Advanced, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03093922 is a Phase 2 study of Urothelial Carcinoma and Locally Advanced that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 32 participants, below the 239-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (87% lower). The trial reports 9 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03093922, a Phase 2 study of Urothelial Carcinoma and Locally Advanced, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to compare any good and bad effects the study drug atezolizumab has on the cancer when combined with the standard chemotherapy drugs gemcitabine and cisplatin (or GC) in two different dosing schedules: chemotherapy (GC) before atezolizumab vs. GC after atezolizumab.
Primary Outcome
with response determined according to RECIST v1.1
Conditions Studied
Interventions
- DRUG Atezolizumab
- DRUG Cisplatin
- DRUG Gemcitabine
Study Locations (9)
New York
- Memorial Sloan Kettering Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen - Montvale
Illinois
- University of Chicago - Chicago
Ohio
- Ohio State University - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2017-03-22 |
| Est. Completion | 2026-03 |
| Phase | Phase 2 |
What the registry record for NCT03093922 still lists
NCT03093922 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 239-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (87% lower).
The record links to 3 conditions, with Urothelial Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Atezolizumab is the first listed.
NCT03093922 lists 9 locations in 4 states (New York, New Jersey, Illinois).
Frequently Asked Questions
What is clinical trial NCT03093922 about?
NCT03093922 is a clinical study titled "A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer". The purpose of this study is to compare any good and bad effects the study drug atezolizumab has on the cancer when combined with the standard chemotherapy drugs gemcitabine and cisplatin (or GC) in two different dosing schedules: chemotherapy (GC) before atezolizumab vs. GC after atezolizumab.
What is the current status of trial NCT03093922?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2017-03-22. Estimated completion is 2026-03.
What conditions does trial NCT03093922 study?
This clinical trial studies the following conditions: Urothelial Carcinoma, Locally Advanced, Unresectable.
What interventions are being tested in trial NCT03093922?
The interventions under investigation include: Atezolizumab (DRUG), Cisplatin (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT03093922?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03093922 being conducted?
This trial has 9 study locations across Illinois, New Jersey, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urothelial Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03093922's enrollment target sits among peer trials
32 62nd of 85 higher than 23 of 85 other Urothelial Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Urothelial Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
RECRUITING · Phase 2
-
Circulating Tumor DNA Response In Urothelial Cancer
RECRUITING · Phase 2
-
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
RECRUITING · Phase 2
-
Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma At High-Risk Recurrence
RECRUITING · Phase 2
-
A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract
RECRUITING · Phase 2
-
Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI